| 王安平.减重药物相关指南与共识解读[J].内科急危重症杂志,2026,32(4):331-336 |
| 减重药物相关指南与共识解读 |
|
| |
| DOI：10.11768/nkjwzzzz.202608061045 |
| 中文关键词: 肥胖 体重管理 减重药物 GLP-1受体激动剂 指南解读 |
| 英文关键词: Obesity Weight management Anti-obesity medications glucagon like peptide-1 receptor agonists Guideline interpretation |
| 基金项目: |
|
| 摘要点击次数: 54 |
| 全文下载次数: 39 |
| 中文摘要: |
| 摘要 近年来，随着肥胖及其相关代谢性疾病患病率持续上升，体重管理已从生活方式干预为主的辅助策略，逐步发展为以循证药物治疗为核心的长期慢病管理模式。多部国内外指南与专家共识相继更新，对减重药物尤其是以胰高糖素样肽-1受体激动剂（GLP-1RA）为代表的肠促胰素类药物在肥胖及相关共病管理中的治疗定位作出了系统阐述。本文结合近年来发布的国际及中国指南与共识，重点解读体重管理理念的演变、减重药物推荐策略的循证基础及其在综合代谢管理中的临床意义，以期为临床实践提供参考。 |
| 英文摘要: |
| Abstract In recent years, with the continuous rise in the prevalence of obesity and its related metabolic diseases, weight management has gradually evolved from an auxiliary strategy predominantly based on lifestyle intervention into a long-term chronic disease management model with evidence-based pharmacotherapy at its core. Multiple domestic and international guidelines and expert consensus have been updated to systematically expound the therapeutic positioning of anti-obesity medications, particularly incretin-based agents represented by glucagon-like peptide-1 receptor agonists (GLP-1RAs), in the management of obesity and related comorbidities. This article reviews recent international and Chinese guidelines and consensus, with an emphasis on interpreting the evolution of weight management concepts, the evidence-based rationale for anti-obesity drug recommendations, and their clinical implications in comprehensive metabolic management, so as to provide a reference for clinical practice. |
|
查看全文
HTML全文 |
|
| 关闭 |
